Nasal powder approved for migraine

The U.S. Food and Drug Administration has approved the use of dihydroergotamine nasal powder (Atzumi) to treat patients with acute migraines.

The dihydroergotamine nasal powder formulation is designed to be administered via an intranasal system, according to a news report from Pharmacy Times.

The FDA’s approval follows positive results from a phase I pharmacokinetic study as well as a phase III clinical trial. Both studies demonstrated that the nasal powder achieved rapid absorption and sustained plasma concentrations of dihydroergotamine.

Despite the results of the trials, the treatment resulted in adverse effects such as rhinitis, pharyngitis, altered taste, nausea, dizziness, somnolence, vomiting and diarrhea and included a boxed warning and contraindications.

Read more: Pharmacy Times

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.